Myelofibrosis

Getting a Myelofibrosis Diagnosis in My 40s

MF has absolutely altered the course of my life and changed how I live it. The range of symptoms even with treatment, takes a toll on functioning especially when you’re trying to take care of others.

How I Manage Myelofibrosis

Despite the recent developments in understanding the molecular biology of MF and treatment with JAK inhibitors, which have shown significant clinical benefits for the patients, there remains an unmet need for the condition, due to its molecular and clinical heterogeneity with high degrees of variability from patient to patient...

My Father, Myelofibrosis, and Me

I know from following my father’s struggles that treating myelofibrosis is more of an art than a science, even with highly skilled physicians involved.

Bob: What I Learned on My Journey With Myelofibrosis

After a few visits to local doctors, a hematologist looked at me and said, “You’re only 28. I had thought I would be telling you that you have something like mononucleosis. But you have primary myelofibrosis (MF).”

CTI BioPharma

The underlying factors driving myelofibrosis might surprise you.

Myelofibrosis Clinical Trials

We help you match, qualify, and enroll into a cancer clinical trial. We believe all cancer patients should have equal access to new therapies regardless of where you live or your ability to pay.

Myelofibrosis Research

Have you been diagnosed with myelofibrosis? Learn about an investigational medication targeting myelofibrosis.

MPN Research Foundation

Classified as a myeloproliferative neoplasm (MPN), MF can arise on its own or as a progression of polycythemia vera (post-PV-MF) or essential thrombocythemia (post-ET-MF). The manifestations of MF, post-PV-MF and post-ET-MF are virtually identical and treatment is generally the same for all three.

Voices of MPN

Each individual journey with MF is unique, and how it may change over time can vary from person to person. It often develops slowly, which may allow some people to live with MF for years without symptoms. However, in other people it may worsen over time.

Jakafi

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is used to treat adults with certain types of myelofibrosis.

Cancer Research UK

Myelofibrosis can affect people of any age. But it usually affects middle-aged and older people. The average age at diagnosis is 65 years.

Myelofibrosis in 2019: moving beyond JAK2 inhibition

Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation to acute myeloid leukemia.

NORD

Primary myelofibrosis belongs to a group of diseases known as the myeloproliferative neoplasms (MPNs). This group of disorders is characterized by the overproduction (proliferation) of one or more of the three main blood cell lines – red or white blood cells or platelets.